BioSpace News Archive

The ŌNŌ endovascular retrieval system was recently used to remove a malpositioned leadless pacemaker (LPM) that embolized to the right pulmonary artery in a 52- year-old patient, ŌNŌCOR LLC announced today.

Neogen Corporation (NASDAQ: NEOG), a leader in food and animal safety, announced today that it has appointed two new members to its Board of Directors: Jeffrey Capello and Aashima Gupta.

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, announced that it has been awarded a three-year contract by Our Future Health.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Chief Executive Officer, Robert Spignesi, will speak at the 2022 PDA/FDA Joint Regulatory Conference.

Brand Institute is proud to announce its work with Revance Therapeutics in developing the brand name DAXXIFY™, which was approved by the FDA on September 7, 2022.

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical biomarker data from its study of LNS8801 as a monotherapy and in combination with pembrolizumab at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting in Paris.

Hansa Biopharma, “Hansa” (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announce the recommendation by the Scottish Medicines Consortium (SMC) for its first-in-class treatment Idefirix® in the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.

SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce positive data confirming safety and efficacy of its Bio-Courier™ next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for Autosomal Dominant Osteopetrosis 2 (ADO2) siRNA therapy.

Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, provides an update on it AcuVid™ COVID-19 Rapid Antigen Saliva Test’s Emergency Use Authorization application with the U.S. Food and Drug Administration.

The treatment for lung infections has conventionally been led by small molecule therapies.